CBIO · XBRL financial data

Crescent Biopharma financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (CBIO's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25†Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	—	—	—	—	—	—	0	0	—	year only	1,039	0
Research and development	5,292	5,288*	6,025	6,286	1,715	11,561*	15	12,081	20,347	95,027*	17,903	19,391
General and administrative	4,522	4,312*	5,090	4,072	4,006	2,999*	2,384	8,949	5,538	7,309*	7,865	8,743
Total operating expenses	9,813	9,601*	11,115	10,358	11,234	14,560*	2,399	21,030	25,885	102,336*	25,768	28,134
Operating income (loss)	(9,813)	(9,591)*	(11,115)	(10,358)	(11,234)	(14,560)*	(2,399)	(21,030)	(25,885)	(91,492)*	(24,729)	(26,364)
Interest expense	—	—	—	—	—	852*	1,112	1,073	0	0*	0	0
Other income (expense)	—	—	—	—	—	—	(924)	(760)	1,278	—	1,446	1,527
Income tax expense (benefit)	—	—	—	—	—	0*	0	0	0	2,000*	0	0
Net income (loss)	(9,203)	(9,079)*	(10,737)	(10,095)	(9,824)	(15,236)*	(2,344)	(21,790)	(24,607)	(23,300)	(23,283)	(24,837)
Earnings per share, basic‡ USD per share	(14.00)	(14.00)*	(17.00)	(16.00)	(15.00)	—	(4.00)	—	—	—	—	—
Earnings per share, diluted‡ USD per share	(14.00)	(14.00)*	(17.00)	(16.00)	(15.00)	—	—	—	—	—	—	—
Weighted average shares, basic‡ thousands of shares	643	643*	645	645	645	645*	645	—	—	—	—	—
Weighted average shares, diluted‡ thousands of shares	643	643*	645	645	645	645*	—	—	—	—	—	—

‡ Per-share figures and share counts are adjusted for the 1-for-100 stock split (June 2025); filings made before it reported them unadjusted.
† Share count changed about 22x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 2x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (CBIO's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25†Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	49,408	41,793	31,281	22,386	14,392	10,720	5,614	152,645	133,265	213,192	189,163	171,593
Accounts receivable	—	—	—	—	—	0	—	—	—	18,000	0	0
Prepaid and other current assets	2,602	1,998	1,986	1,471	1,254	371	378	1,582	1,298	5,463	6,400	7,413
Total current assets	52,010	43,791	33,267	23,858	15,646	11,091	5,992	154,227	134,563	236,655	195,563	179,006
Property and equipment, net	133	—	—	—	—	0	—	193	782	846	929	876
Right-of-use asset	955	768	598	424	—	0	—	1,607	1,564	1,469	1,372	1,271
Total assets	53,201	45,316	34,205	24,419	15,698	11,091	5,992	157,433	138,269	240,293	199,130	182,758
Accounts payable	330	868	756	951	582	329	105	—	—	—	—	—
Accrued liabilities	5,311	5,226	3,908	2,957	3,478	5,382	2,512	7,608	8,965	16,344	4,433	7,407
Total current liabilities	6,391	6,835	5,294	4,356	4,322	5,778	2,617	16,746	20,304	36,072	14,193	18,537
Lease liability, non-current	262	67	—	—	—	0	—	1,433	1,324	1,209	1,090	966
Total liabilities	6,653	6,902	5,294	4,356	4,322	5,778	2,617	18,179	21,628	37,281	15,283	19,503
Accumulated deficit	(447,407)	(456,485)	(467,222)	(477,317)	(487,142)	(494,364)	(496,708)	(54,805)	(79,412)	(171,809)	(195,092)	(219,929)
Total stockholders' equity	46,548	38,414	28,911	20,063	11,376	5,314	3,375	139,254	116,641	203,012	183,847	163,255
Total liabilities and equity	53,201	45,316	34,205	24,419	15,698	11,091	5,992	157,433	138,269	240,293	199,130	182,758
Common shares outstanding (cover page)‡ thousands of shares	644	645	645	645	645	645	645	13,893	13,893	27,557	27,572	37,144

‡ Per-share figures and share counts are adjusted for the 1-for-100 stock split (June 2025); filings made before it reported them unadjusted.
† Share count changed about 22x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 2x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (CBIO's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25†Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25†Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(9,203)	(9,079)*	(10,737)	(10,095)	(9,824)	(15,236)*	(2,344)	(21,790)	(24,607)	(23,300)	(23,283)	(24,837)
Stock-based compensation	888*	908*	1,192	1,207*	1,138*	1,065*	405	6,164*	1,986*	4,745*	4,113	3,965*
Net cash from operating activities	(8,683)*	(7,615)*	(10,509)	(8,893)*	(7,994)*	(6,269)*	(5,106)	(22,147)*	(17,539)*	(26,740)*	(8,937)	(19,463)*
Purchases of property and equipment	8*	1*	7	3*	0*	0*	0	140*	586*	193*	147	13*
Net cash from investing activities	(8)*	(1)*	(7)	(3)*	0*	0*	0	(140)*	(586)*	(72,193)*	(8,147)	1,757*
Proceeds from issuing common stock	0*	0*	—	—	—	—	—	—	—	year only	—	—
Net cash from financing activities	62*	1*	5	1*	0*	41,035*	(1,486)	146,864*	(1,254)*	178,860*	(6,945)	136*
Net change in cash	(8,629)*	(7,615)*	(10,511)	(8,895)*	(7,994)*	34,766*	(5,106)	123,091*	(19,379)*	79,927*	(24,029)	(17,570)*

† Share count changed about 22x in the period ending 2025-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
† Share count changed about 2x in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Crescent Biopharma	171,593	0	(19,463)*	37.1M	8.8 quarters	Q2 FY26 10-QJun 30, 2026
Omeros	1,988	28,529	4,149*	72.4M	—	Q2 FY26 10-QJun 30, 2026
Lexicon Pharmaceuticals	40,924	692	(9,192)*	445.0M	20.7 quarters	Q2 FY26 10-QJun 30, 2026
XOMA Royalty	85,600	12,318	6,121	12.5M	—	Q1 FY26 10-QMar 31, 2026
4D Molecular Therapeutics	70,372	3,781	(69,999)*	55.2M	5.2 quarters	Q2 FY26 10-QJun 30, 2026
Editas Medicine	181,815	11,890	(29,568)*	153.6M	7.2 quarters	Q2 FY26 10-QJun 30, 2026
Lineage Cell Therapeutics	37,355	1,069	(7,244)*	252.9M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Palvella Therapeutics	187,803	not reported	(12,845)*	14.4M	19.5 quarters	Q2 FY26 10-QJun 30, 2026
Esperion Therapeutics	156,158	80,104	(27,722)	257.4M	5.6 quarters	Q1 FY26 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.